In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

In separate filings, Chief Legal Officer Soleil Boughton sold 2,572 shares at a price of $51.64 apiece for $132,818, while ...

Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses from the stock lately, following its ...

Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

While Wall Street analysts remain cautious on Hims & Hers Health ($HIMS), TipRanks’ A.I. Stock Analysis tool shows strong ...

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...